Primary and key secondary end points across all cohorts in the primary and entire treatment periods. TD patients: anemia response defined as 12 consecutive weeks without RBC transfusion; NTD patients: anemia response defined as 12 consecutive weeks with ≥1.5 g/dL Hb increase from baseline without transfusion. Values above bars show % patients; top panel shows % patients (95% CI). RUX, ruxolitinib.